Company Performance: Globus Medical Inc. (NYSE: GMED) reported a 3% year-over-year sales increase and adjusted earnings per share of $0.86, surpassing analyst expectations, while operational issues have improved significantly.
Investment Outlook: Despite the positive performance, analysts suggest that certain AI stocks may offer better upside potential and lower risk compared to GMED as an investment.
GMED
$85.79+Infinity%1D
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 92.22 USD with a low forecast of 64.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 92.22 USD with a low forecast of 64.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 86.500
Low
64.00
Averages
92.22
High
114.00
Current: 86.500
Low
64.00
Averages
92.22
High
114.00
Freedom Capital
Hold
initiated
$87
2025-12-16
New
Reason
Freedom Capital
Price Target
$87
2025-12-16
New
initiated
Hold
Reason
Freedom Capital initiated coverage of Globus Medical with a Hold rating and $87 price target. The firm says the company's "solid" organic growth is already reflected in the shares.
BofA
Travis Steed
Buy
maintain
$91 -> $106
2025-12-08
Reason
BofA
Travis Steed
Price Target
$91 -> $106
2025-12-08
maintain
Buy
Reason
BofA analyst Travis Steed raised the firm's price target on Globus Medical to $106 from $91 and keeps a Buy rating on the shares. The Street is modeling only 70 basis points of operating margin expansion in 2026, but the firm thinks Nevro alone could help total company operating margins by 110 basis points, the analyst tells investors.
Morgan Stanley
Patrick Wood
Overweight
maintain
$70 -> $100
2025-12-02
Reason
Morgan Stanley
Patrick Wood
Price Target
$70 -> $100
2025-12-02
maintain
Overweight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Globus Medical to $100 from $70 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Truist
Buy
maintain
$93 -> $105
2025-11-18
Reason
Truist
Price Target
$93 -> $105
2025-11-18
maintain
Buy
Reason
Truist raised the firm's price target on Globus Medical to $105 from $93 and keeps a Buy rating on the shares. The firm cites multiple expansion in the comp group for the price target update.
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
